scorecardresearch
Add as a preferred source on Google
Wednesday, April 22, 2026
TopicSpinal Muscular Atrophy

Topic: Spinal Muscular Atrophy

Roche patent case: Why SC refused to halt Natco’s generic spinal muscular atrophy drug Risdiplam

Roche had approached Delhi High Court, accusing Natco of violating its Indian patent, before going to the Supreme Court with its petition.

India approves Zolgensma, one of world’s costliest drugs. Why it’s sparked hope, but also concern

Zolgensma is the only drug that promises a cure for Spinal Muscular Atrophy, provided it is administered to affected children before the symptoms appear.

New hope for rare disease patients: Rs 900-cr govt project to get high-value drugs at lower rates in works

India has 8.4 to 19 crore rare disease patients, according to health ministry estimates. But current beneficiaries in most cases are kids or those who need relatively less expensive drugs.

On Camera

Why ‘disgustingly well-read’ is a win for modern literacy

Like most social media trends, the 'disgustingly well-read' trend, too, is without a doubt problematic, performative, and for some, perfunctory

FTA partners drive India’s trade surge as reliance on non-FTA countries dips, says NITI Aayog report

Share of trade with FTA partners rose from 4.6% in 2006 to 28.8% in 2024. India is currently negotiating or advancing agreements with US, Israel, GCC, Canada & Mexico.

Japan overhauls post-World War II pacifist military approach, lifts restrictions on defence exports

Since October last year, Japan PM Sanae Takaichi has planned to increase defence spending target to 2 percent of GDP.

Trump, Netanyahu’s Iran gamble: The regime change rebound

American objectives are unmet. They neither have muscle nor motivation to resume the war. As for Iran, the regime didn’t just survive, it’s now led by more radical individuals.